ArticleBMC cancer2025

RC48-ADC monotherapy or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma with HER2 low and null expression: a multicenter, real-world, retrospective study.

Daining Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.